Therapeutic Drug Monitoring: Last Dose, Sample Time and Interpretation
Document actual dosing and collection times, formulation and test purpose; distinguish a twelve-hour lithium sample from other medicine-specific monitoring plans.
Review a culture report against the original specimen, current clinical condition and antibiotics actually taken. Confirm whether the report is preliminary, final or amended and which susceptibility standard the laboratory used. The clinician may continue, change or stop treatment after interpretation; neither 'sensitive' nor an assumed day-three deadline is an automatic prescription instruction. Close the loop with a documented decision and patient communication.
Indian OPD clinicians and clinic teams following urine, wound and other microbiology results after an initial consultation.
Before reading the susceptibility grid, identify the patient, specimen site, collection date and clinical reason for the investigation. A urine culture, surface wound swab and specimen collected during a procedure answer different questions. A filename containing only the patient's name cannot safely represent that distinction.
Recover the relevant collection account, including prior treatment and any quality comment. A positive result must be interpreted in context; a cultured organism is not by itself a complete diagnosis. The doctor may need clarification from the laboratory about mixed growth, specimen suitability or the significance of the reported organism.
ICMR's antimicrobial-use guidance links modification of empirical therapy to culture and susceptibility findings together with patient status. That supports an interpretation step, not an automatic switch to the first medicine marked susceptible. No drug-selection regimen is supplied by this article.
Source: ICMR: Guidelines for Antimicrobial Use — de-escalation and modification
Microbiology information may arrive in stages: an early notification, organism identification, susceptibility results and a later correction. Record the report's own status and version. An uploaded PDF is not necessarily final simply because it has a laboratory logo or a signature.
If an important telephone result is received, document the caller, laboratory, patient/specimen identifiers, message and action under the clinic's procedure. Reconcile it with the later written report. A phone note and PDF may concern the same specimen, so they should not create two unrelated review tasks.
An amendment should draw attention to the changed content and the prior decision it could affect. Preserve the earlier version and who reviewed it. Replacing the file silently can make a subsequent clinician believe the original treatment decision was made using information that did not exist at the time.
EUCAST's current definitions distinguish susceptibility at standard exposure from susceptibility requiring increased exposure; its I category is not simply equivalent to resistance. EUCAST also says not to group I with R as a generic non-susceptible category. This applies to reports using that system, not automatically to every laboratory's abbreviations.
Ask which interpretive standard and relevant version the laboratory used when the legend is unclear. Preserve the original wording, units and comments. Do not convert a letter into a patient-facing green/red instruction or let a software colour select a medicine.
Exposure, infection site, product, renal context, interactions and patient circumstances require clinical interpretation. The appropriate response to uncertainty may be a microbiology or specialist discussion. This guide does not turn the EUCAST definition into a dose-escalation instruction.
The following original matrix makes the review more informative than a 'culture seen' checkbox. Different evidence can change the decision for different reasons.
On a narrow screen, scroll the table horizontally to read all columns.
| Review element | Question to resolve | Record to retain |
|---|---|---|
| Clinical course | How is the patient now, and is assessment urgent? | Current account, examination if performed and care action |
| Actual antibiotic use | What product and regimen was actually taken? | Verified or qualified use history, not only the old prescription |
| Specimen context | Does the result address the original clinical question? | Site, collection time, quality comments and relevant prior treatment |
| Report status | Is this preliminary, final or amended? | Source version and links to earlier notifications |
| Susceptibility meaning | Which system and comments apply? | Original categories, laboratory clarification and uncertainty |
| Clinical decision | Continue, modify, stop or seek more information? | Responsible clinician, rationale and authorised plan |
| Communication | Has the patient received and understood the current plan? | Recipient, actual contact outcome and unresolved action |
A 'day-three review' sentence can hide several different clocks: three days after prescribing, collection, laboratory receipt or report release. Record actual events. The required urgency depends on the patient and information received, and a deteriorating patient should not wait for a routine calendar reminder.
Assign the result to a clinical owner and an alternate. A solo doctor who is away needs an explicit handover for incoming reports, not a queue that appears assigned but is unattended. Establish how the laboratory sends urgent notifications and how the clinic acknowledges them.
Patient contact is another stage. 'Doctor reviewed' does not establish that a changed instruction reached the person taking the medicine. For a shared family number, verify the intended recipient and appropriate disclosure before sending detailed clinical information.
Document what the clinician decided and why, using the current clinical picture and the report. Continuing treatment may be a considered decision; changing it may require a new prescription and explanation. Neither should be inferred from opening a PDF.
If the plan changes, reconcile existing medicines and copies through the clinic's correction process. Explain the authorised current instruction and resolve uncertainty about old supplies. A note saying 'changed as per sensitivity' is too vague for a second clinician or a pharmacist trying to understand what the patient should now follow.
When the patient cannot be reached, record the attempts and route the unresolved task according to clinical urgency. Do not mark the episode complete because a message was sent or a telephone rang. Keep evidence of contact separate from assumptions about adherence.
In a fictional weekly review, ten culture specimens produce twelve report files because two specimens each have an amendment. Eight specimen episodes have a documented clinical decision; six also have confirmed patient communication. The figures are ten specimens, twelve files, eight decisions and six completed communication records.
Calling twelve files 'twelve reviewed patients' inflates the denominator. Calling all eight clinical decisions 'closed loops' conceals two communication gaps. A useful local measure should define the episode and the completion event before calculating a percentage.
Use the outline below to preserve these distinctions. It supports operational review; it does not evaluate antibiotic appropriateness or certify stewardship outcomes.
A doctor reviews a preliminary culture message and records a plan. The next day an amended laboratory report changes relevant information. The clinic links it to the same specimen episode, preserves the first decision and requests a new clinical review. The resulting patient instruction is communicated and documented separately. The amendment is not counted as a second patient, and the earlier 'reviewed' state cannot conceal the new task.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. The clinician interprets the specimen, susceptibility findings, clinical course and actual medicine use before deciding whether to continue, modify or stop treatment.
No. Under EUCAST it represents susceptibility requiring increased exposure. Confirm the reporting system and laboratory comments; do not infer a dose change from the letter alone.
A fixed day-three assumption cannot replace actual report availability and clinical urgency. Record the relevant times and ensure an accountable review pathway, including urgent notifications.
Link the amendment to the original specimen, retain earlier versions and reassess any decision affected by the change. A previously completed task may need to reopen.
No. Clinical interpretation, prescription revision and patient communication are separate actions. Preserve the actual contact outcome and any unresolved task.
Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.
Indian guidance connects culture/AST to patient status. Used for the review principle, not a universal day-three rule or reproduced antibiotic regimen.
Interpretive categories for laboratories using EUCAST. The actual report's standard and version must be established.
Document actual dosing and collection times, formulation and test purpose; distinguish a twelve-hour lithium sample from other medicine-specific monitoring plans.
Prepare timed urine and sputum handovers with a worked incomplete-collection timeline, laboratory exception note and practical collection-site checks.
Tie each proposed test to the procedure, patient and decision, reconcile outside results and medicine plans, and avoid treating a panel as blanket clearance.
Trace a fictional culture episode with preliminary and amended reports, an explicit clinician decision and a failed first contact; verify that files, patients and completed handovers are counted separately.
Request a clinic demo